Meridian Bioscience Inc (VIVO) Return on Equity ROE from the first quarter 2023 to first quarter 2022 and annually, average high and low, overall ranking from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Meridian Bioscience Inc   (NASDAQ: VIVO)

Meridian Bioscience Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Meridian Bioscience Inc in the first quarter 2023?
Meridian Bioscience Inc recorded a cumulative net loss of $-3 million during 12 months ending in the first quarter 2023, resulting in a negative return on equity (ROE) of -0.75%.

Within the In Vitro & In Vivo Diagnostic Substances industry 5 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2022 from 0 to 1004.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2022)
I. Quarter		 (Sep 30 2022)
IV. Quarter		 (Jun 30 2022)
III. Quarter		 (Mar 31 2022)
II. Quarter		 (Dec 31 2021)
I. Quarter
Y / Y Equity Change -1.36 % 12.11 % 13.47 % 21.05 % -
Y / Y Net Income Change - -14.3 % - 9.31 % -42.72 %
Net Income (TTM) in Millions -3 42 43 62 60
Return On Equity (TTM) -0.75 % 11.68 % 12.28 % 18.22 % 18.38 %
VIVO's Total Ranking # 1004 # 0 # 1406 # 978 # 1063
Equity (TTM) in Millions 341 368 366 375 345
Seq. Equity Change -7.48 % 0.69 % -2.43 % 8.52 % 5.15 %
Seq. Net Income Change - - - 87.43 % 130.43 %

Back to VIVO Management Effectiveness >> VIVO's 5 Years Annual ROE >> Compare VIVO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 6
Sector # 232
Overall # 1004

Return On Equity Statistics
High Average Low
32.57 %
18 %
-0.75 %
(Mar 31 2021)  





VIVO Annual Return On Equity (Sep 30 2022)
2022		 (Sep 30 2021)
2021		 (Sep 30 2020)
2020		 (Sep 30 2019)
2019		 (Sep 30 2018)
2018
Total Equity in Millions 368 328 248 191 175
Y / Y Equity Change 12.11 % 32.58 % 29.67 % 8.86 % 3.44 %
Net Income in Millions 42 71 46 24 24
Y / Y Net Income Change -40.54 % 54.61 % 89.43 % 2.23 % 10.63 %
Return On Equity 11.54 % 21.75 % 18.65 % 12.77 % 13.6 %

Back to VIVO Management Effectiveness >> VIVO's 5 Years Annual ROE >> Compare VIVO ROE to its Competitors




Annual Roe Comment
In 2022 ROE decreased compared to the previous year to 11.54 %, due to deterioration of net income.


More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VIVO's' Return on Equity at Yahoo Finance
VIVO's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VIVO's Competitors
Subscribers only: Roe for Meridian Bioscience Inc 's Suppliers
Subscribers only: Return On Equity for VIVO's Customers




Companies with similar Return On Equity at Dec 31 2022, within Healthcare Sector ROE

Date modified: 2026-09-26T06:55:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.